Evaluating Due Diligence Standards: The Theranos Case and Life Sciences Investment Challenges

Jason Lemkin argues that investors in Theranos did not necessarily perform poor due diligence, noting that evaluating truly disruptive science is inherently difficult. He draws parallels to his own NanoGram Devices experience, where even world-renowned experts and the founder couldn't fully understand how innovative technology worked, highlighting that life sciences due diligence requires different expertise than IT venture capital.